Disease relevance of AIDS027578

• This study demonstrates that 5,6-dihydro-5-azacytidine in the dose and schedule used has no significant therapeutic activity in the treatment of lung cancer but does possess an unusual spectrum of clinical toxicities as well as the property of inducing fetal hemoglobin synthesis [1].
• Fifteen of the 17 patients who received 5,6-dihydro-5-azacytidine developed a pleuritic-type chest pain, 12 had abnormal electrocardiograms, and four developed positive anti-nuclear antibodies [1].
• Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma [1].
• The comparative effects of 5-azacytidine and dihydro-5-azacytidine on polysomal RNA in Ehrlich ascites cells in vitro [2].
• Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma [3].

High impact information on AIDS027578

• Effects of dihydro-5-azacytidine on cell survival and cell cycle progression of cultured mammalian cells [4].
• The effect of 5-azacytidine and dihydro-5-azacytidine on nuclear ribosomal RNA and poly(A) RNA synthesis in L1210 cells in vitro [5].
• The plasma kinetics of 5,6-dihydro-5-azacytidine (DHAC) was determined in mice using an HPLC method following an intravenous dose of 2000 mg/kg (LD10) [6].
• Studies on the cytostatic action, phosphorylation and deamination of 5-azacytidine and 5,6-dihydro-5-azacytidine in HeLa cells [7].
• Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-) [8].

Chemical compound and disease context of AIDS027578

• In previous clinical trials in mesothelioma, the cytidine analog dihydro-5-azacytidine (DHAC) has been found to induce clinical responses in approximately 17% of patients with mesothelioma treated with this drug, including prolonged complete responses [9].
• A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma [10].

Biological context of AIDS027578

• Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor [6].
• Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163 [11].

Analytical, diagnostic and therapeutic context of AIDS027578

• CONCLUSIONS: In malignant mesothelioma, a disease that is refractory to chemotherapy, dihydro-5-azacytidine has definite antitumor activity [12].

References